Braveheart Bio is a startup based in the Netherlands, 1 tracked investor.
Braveheart Bio is a startup based in the Netherlands. Brouky records 1 investor associated with the company.
Braveheart Bio is a clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions. The company is advancing BHB-1893, a selective cardiac myosin inhibitor, through late-stage clinical development with the goal of establishing a new standard of care for patients with HCM.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.